A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Trial Profile

A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Colorectal cancer vaccine-Vaccinogen (Primary)
  • Indications Colon cancer
  • Focus Therapeutic Use
  • Acronyms ACTIVE
  • Sponsors Vaccinogen
  • Most Recent Events

    • 14 May 2015 Status changed from planning to recruiting as reported by ClinicalTrials.gov record.
    • 23 Feb 2015 New trial record
    • 17 Feb 2015 Enrolment is expected to be initiated within 60 days of obtaining adequate funding, according to a Vaccinogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top